A five drug combination drug therapy trial has shown substantial tumour shrinking in more than half of patients, with some tumours disappearing completely, in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

DLBCL is recognised as the most common lymphoma, accounting for up to 30% of all non-Hodgkin lymphoma cases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The National Institute of Health (NIH) ran a single-centred Phase Ib/II study (NCT03223610) of 50 patients at NIH’s National Cancer Institute (NCI) used a combination of AbbVie’s Venclexta (venetoclax), AbbVie’s Imbruvica (ibrutinib), prednisone, Roche’s Gaziva (Obinutuzumab), and BMS’s Revlimid (lenalidomide), named ViPOR.

The researchers selected the five drugs after conducting pre-clinical laboratory studies analysing which targeted drugs could best be combined to kill DLBCL cells.

The Phase Ib portion of the trial was a dose identifying study for Venclexta. The Phase II portion used the pre-determined Venclexta dose with fixed doses of the other four drugs.

At a two-year follow-up point, the treatment had shrank tumours substantially in 54% of evaluable patients, with complete response (CR) in 38% of patients.

The trial also reported 36% overall survival (OS) and 34% progression-free survival (PFS). In addition, circulating tumour DNA was undetectable in 33% of patients.

Full findings of the study have been published in the New England Journal of Medicine.

“DLBCL is one of the most genetically heterogeneous forms of cancer, and as a result we don’t yet have the ability to identify exactly which combination of drugs would be most effective for any given patient,” said Dr. Christopher Melani of NCI’s Center for Cancer Research and co-lead on the study.

“By putting five drugs together, we believe that there will be some drug combination—either two, three, or more drugs—that will be particularly effective against that patient’s tumour.”

Elsewhere in lymphoma, Roche recently reported findings from its Phase III STARGLO (NCT04408638) trial, finding that Columvi (glofitamab), in combination with GemOx (gemcitabine and oxaliplatin), significantly extended survival in patients with R/R DLBCL.

In March 2024, GenFleet Therapeutics signed a clinical trial collaboration and supply agreement with BeiGene Switzerland for the enactment of a Phase Ib/II clinical trial of GFH009 and BRUKINSA (zanubrutinib) to treat DLBCL.